| CONTENTS |
| Introduction: Protein Pharmaceuticals: Recent Achievements and Trends for Formulation and Delivery Henrik L Luessen, Tytonis BV, and Gerrit Borchard, University of Geneva |
| Lipid Liquid Crystals for Parenteral Sustained-Release Applications: Combining Ease of Use and Manufacturing with Consistent Drug Release Control Fredrik Tiberg, PhD, Prof, President & CEO, and Fredrik Joabsson, PhD, Director, Drug Delivery Systems and Technical Business Development Camurus AB |
| Company profile Nanomi BV |
| Intrathecal Delivery of Protein Therapeutics to Treat Genetic Diseases Involving the CNS Zahra Shahrokh, PhD, Senior Director, Pharmaceutical and Analytical Development, Perry Calias, PhD, Senior Director, Nonclinical Development, and Lawrence Charnas, MD, PhD, Medical Director Shire Human Genetic Therapies, Inc |
| Dendrimers Enhance Delivery of Small-Molecule and Biological Drugs: Control Solubility, Half-Life, Toxicity and Targeting David Owen, PhD, VP Research, and Paul Barrett, PhD, VP Business Development Starpharma Holdings Limited |
| Contrasol™: Novel Nanotechnology for the Enhanced Development of Intravenous Formulations Alison Foster, PhD, Laboratory Director IOTA NanoSolutions, Ltd |